Who Owns Coram?

Coram's sustainability initiatives are part of CVS Health's corporate environmental and social responsibility programs. CVS Health has set science-based targets for reducing greenhouse gas emissions, including a commitment to achieve net-zero emissions by 2050.

CVS Health has invested in renewable energy, completing seven renewable energy investments since 2022. These investments include power purchase agreements representing more than 870,000 megawatt hours of clean renewable energy, expected to power approximately 3,000 CVS Health locations by 2026.

CVS Health has also implemented sustainable transportation initiatives, including its first fully electric truck at a distribution center in Patterson, California, and electrified trailer parking spots at a facility in La Habra, California. These initiatives extend to Coram's distribution and nursing service logistics.

As a healthcare provider, Coram's primary ethical responsibilities involve patient safety, quality of care, and regulatory compliance. Coram maintains a Pharmacy Quality Program that includes a microbiology laboratory for environmental testing of sterile compounding clean rooms. The brand adheres to USP 797 and USP 800 standards for sterile compounding and hazardous drug handling.

Coram's operations are subject to extensive federal and state regulations governing specialty pharmacy, sterile compounding, controlled substances, and patient privacy (HIPAA). The brand maintains accreditation from relevant healthcare quality organizations.

The October 2024 service reductions raised ethical questions about patient care continuity. CVS Health stated that it had a comprehensive transition plan to work with patients, providers, and health plans to safely transition affected patients to alternative providers. However, patient advocates and healthcare providers expressed concerns about the availability of alternative home infusion providers in certain regions.

Coram does not have publicly documented individual brand-level awards. The brand's recognition comes primarily from its clinical quality programs and accreditation status.

Coram's Pharmacy Quality Program, including its microbiology laboratory for environmental testing of sterile compounding facilities, has been recognized within the specialty pharmacy industry as a model for quality assurance. The program enables rigorous and frequent environmental testing across all Coram pharmacies.

Coram's clinical team of nurses, dietitians, and pharmacists has been recognized for delivering infusion therapies to more than 50,000 patients per month with conditions including immune deficiencies, Crohn's disease, and rheumatoid arthritis.

CVS Health, as Coram's parent company, has received corporate recognition for sustainability and healthcare innovation, but these awards apply to CVS Health as a whole rather than to Coram specifically.

The most significant issue in Coram's recent history is the October 2024 decision by CVS Health to exit core infusion services. CVS stopped accepting new patients for antibiotics, inotropic medications, total parenteral nutrition, and acute home infusion therapies. The company planned to close or sell 29 regional pharmacies associated with these services.

The decision was attributed to challenging industry conditions. "Providers of infused medications have continued to face a challenging environment for their most highly specialized, complex services, and Coram has not been immune to these challenges," a CVS spokesperson said. The challenges included reimbursement pressures, labor costs, and supply shortages.

The service reduction raised concerns about patient access to home infusion therapy. Healthcare providers and patient advocates expressed concerns about maintaining continuity of care for affected patients, particularly in regions where alternative providers may not be available. CVS stated that it had a transition plan to work with patients, providers, and health plans.

In 2022, CVS Health closed 36 of 71 Coram clinics and laid off approximately 2,000 employees, including dietitians, nurses, and pharmacists. The closures were attributed to high overhead costs, labor costs, reimbursement delays, and supply shortages. A KFF News report highlighted the financial pressures facing the home infusion industry.

The October 2024 service reduction also raised questions about potential layoffs. CVS stated that impacted employees would be notified in mid-November 2024, with workforce reductions expected to begin in early 2025. These reductions were separate from CVS Health's broader layoff of 2,900 employees announced in September 2024 and an additional 632 employees announced in October 2024.

Coram and CVS Health have faced scrutiny regarding the integrated healthcare model, which combines retail pharmacy, pharmacy benefits management (Caremark), health insurance (Aetna), and specialty pharmacy services. Critics have raised concerns about potential conflicts of interest when the same company that provides infusion services also manages pharmacy benefits and sells health insurance.

The home infusion therapy industry as a whole has faced criticism regarding reimbursement practices. Medicare reimbursement rates for home infusion services have been criticized as inadequate to cover the costs of providing care, contributing to the financial pressures that led to Coram's service reductions.